A citation-based method for searching scientific literature

Hongrong Deng, Shuo Lin, Xubin Yang, Jing Lv, Sihui Luo, Longyi Zeng, Jianping Weng, Wen Xu. J Diabetes 2019
Times Cited: 5







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
M Buysschaert, V Preumont, P R Oriot, I Paris, M Ponchon, D Scarnière, P Selvais. Diabetes Metab 2010
35
40


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
947
40

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Helle Linnebjerg, Soomin Park, Prajakti A Kothare, Michael E Trautmann, Kenneth Mace, Mark Fineman, Ian Wilding, Michael Nauck, Michael Horowitz. Regul Pept 2008
170
40

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Vanita R Aroda, Robert R Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow, Byron J Hoogwerf. Clin Ther 2012
176
40

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
40


Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes.
Sun Ok Song, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee. J Diabetes Investig 2014
13
40

Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Michael Horowitz, Vanita R Aroda, Jenny Han, Elise Hardy, Chris K Rayner. Diabetes Obes Metab 2017
33
40

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Mark S Fineman, K F Mace, M Diamant, T Darsow, B B Cirincione, T K Booker Porter, L A Kinninger, M E Trautmann. Diabetes Obes Metab 2012
105
40

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Carol H Wysham, Leigh A MacConell, David G Maggs, Ming Zhou, Peter S Griffin, Michael E Trautmann. Mayo Clin Proc 2015
42
40

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Carol H Wysham, Julio Rosenstock, Marion L Vetter, Fang Dong, Peter Öhman, Nayyar Iqbal. Diabetes Obes Metab 2018
20
40

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan. Diabetes Care 2014
214
40



American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.
W Timothy Garvey, Alan J Garber, Jeffrey I Mechanick, George A Bray, Samuel Dagogo-Jack, Daniel Einhorn, George Grunberger, Yehuda Handelsman, Charles H Hennekens, Daniel L Hurley,[...]. Endocr Pract 2014
99
20

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
906
20


Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
541
20







Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
454
20


Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study.
Xianghai Zhou, Linong Ji, Xingwu Ran, Benli Su, Qiuhe Ji, Changyu Pan, Jianping Weng, Changsheng Ma, Chuanming Hao, Danyi Zhang,[...]. PLoS One 2016
21
20

Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
Richard Pencek, Amy Blickensderfer, Yan Li, Steven C Brunell, Pamela W Anderson. Postgrad Med 2012
30
20

Evolution of exenatide as a diabetes therapeutic.
Sunil Bhavsar, Sunder Mudaliar, Alan Cherrington. Curr Diabetes Rev 2013
49
20



Erratum. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.
Julie A Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, Leif E Lovblom, Shajiha Khan, Robel Alemu, Amy Locke, Vesta Lai, Huaibing He, Lucinda Hittle,[...]. Diabetes Care 2017
2
50

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
G Derosa, I G Franzetti, F Querci, A Carbone, L Ciccarelli, M N Piccinni, E Fogari, P Maffioli. Diabet Med 2012
45
20


Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes.
William H Herman, Kathleen M Dungan, Bruce H R Wolffenbuttel, John B Buse, Jessie L Fahrbach, Honghua Jiang, Sherry Martin. J Clin Endocrinol Metab 2009
153
20


Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Mathijs C Bunck, Anja Cornér, Bjorn Eliasson, Robert J Heine, Rimma M Shaginian, Marja-Riitta Taskinen, Ulf Smith, Hannele Yki-Järvinen, Michaela Diamant. Diabetes Care 2011
190
20


Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.
Doris A Stoffers, Biva M Desai, Diva D DeLeon, Rebecca A Simmons. Diabetes 2003
195
20


American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.
Yehuda Handelsman, Zachary T Bloomgarden, George Grunberger, Guillermo Umpierrez, Robert S Zimmerman, Timothy S Bailey, Lawrence Blonde, George A Bray, A Jay Cohen, Samuel Dagogo-Jack,[...]. Endocr Pract 2015
337
20

Population pharmacokinetics of exenatide.
Brenda Cirincione, Donald E Mager. Br J Clin Pharmacol 2017
12
20

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
343
20



β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.
Daisuke Yabe, Yutaka Seino, Mitsuo Fukushima, Susumu Seino. Curr Diab Rep 2015
154
20

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
Bidda Rolin, Marianne O Larsen, Carsten F Gotfredsen, Carolyn F Deacon, Richard D Carr, Michael Wilken, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2002
237
20

In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
Su Jin Jung, Ngoc-Thanh Thi Nguyen, Sang Ah Lee, Sung Hwa Seo, Eui-Sung Choi, Hong Weon Lee, Gi Hun Seong, Ok Nam Bae, E K Lee. J Biotechnol 2019
1
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.